Affimed Announces Significant Investment by an Existing Shareholder
HEIDELBERG, Germany, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today announced that an existing shareholder has increased its position in the …